Share This Page
Drug Price Trends for GAMMAGARD LIQUID
✉ Email this page to a colleague
Average Pharmacy Cost for GAMMAGARD LIQUID
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GAMMAGARD LIQUID 10% VIAL | 00944-2700-06 | 10.89704 | ML | 2025-01-01 |
| GAMMAGARD LIQUID 10% VIAL | 00944-2700-10 | 10.15674 | ML | 2025-01-01 |
| GAMMAGARD LIQUID 10% VIAL | 00944-2700-04 | 10.15674 | ML | 2025-01-01 |
| GAMMAGARD LIQUID 10% VIAL | 00944-2700-12 | 10.89704 | ML | 2025-01-01 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Gammagard Liquid
Introduction to Gammagard Liquid
Gammagard Liquid, an immune globulin infusion, is a crucial treatment for various autoimmune and inflammatory conditions, including Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy, and Primary Immunodeficiency Syndrome. Here, we will delve into the market analysis and price projections for this essential medication.
Market Size and Growth
The intravenous immunoglobulin (IVIG) market, which includes Gammagard Liquid, has been experiencing significant growth. As of 2023, the IVIG market size was valued at USD 12.7 billion and is projected to reach USD 23.5 billion by 2034, with a Compound Annual Growth Rate (CAGR) of 5.76% during the forecast period of 2024-2034[1].
Drivers of Market Growth
Several factors are driving the growth of the IVIG market, including:
Increase in Autoimmune and Inflammatory Diseases
The rising prevalence of autoimmune and inflammatory diseases is a key driver. These conditions require effective treatments, and IVIG therapies like Gammagard Liquid are increasingly sought after.
Advancements in Production Technologies
Technological advancements in plasma fractionation and purification processes have improved the quality and consistency of IVIG products. This has helped address previous supply constraints and enhanced the reliability of these treatments[1].
Heightened Awareness and Regulatory Approvals
Increased awareness about the benefits of IVIG therapies, along with recent regulatory approvals such as the FDA approval for Gammagard Liquid for treating CIDP, have further boosted the market[1].
Pricing and Cost Analysis
Current Pricing
The cost of Gammagard Liquid varies based on the quantity and the pharmacy. Here are some current price points:
- 10 milliliters: Around $188, with a per-unit cost of $18.80[2].
- 25 milliliters: Approximately $455.76, with a per-unit cost of $18.23[2].
- 50 milliliters: About $902.02, with a per-unit cost of $18.04[2].
- 100 milliliters: Around $1,794.55, with a per-unit cost of $17.95[2].
Factors Influencing Pricing
Several factors influence the pricing of Gammagard Liquid:
Production Costs
The cost of plasma collection, fractionation, and purification processes contributes significantly to the final price of the product.
Regulatory and Approval Costs
The costs associated with obtaining regulatory approvals, such as FDA clearances, also impact the pricing.
Market Demand and Competition
The demand for IVIG therapies and the competitive landscape among manufacturers like Takeda, Grifols, and CSL can influence pricing strategies[4].
Insurance and Patient Assistance Programs
Prices can vary significantly depending on whether the patient is using insurance or relying on cash payments. Patient assistance programs and discount cards can also reduce the cost[2].
Price Projections
Given the growing demand and advancements in technology, here are some insights into future price projections:
Market Forecast
The global IVIG market, including Gammagard Liquid, is forecasted to grow significantly. By 2030, the market is expected to reach USD 21,530 million, with a CAGR of 7.1% during the forecast period of 2024-2030[4].
Potential Price Stabilization
As technological advancements continue to improve production efficiency and supply chain logistics, there could be a stabilization or even a slight reduction in prices. However, this would depend on various market and regulatory factors.
Impact of Biosimilars
The introduction of biosimilars could potentially reduce the prices of biologic drugs, including IVIG products. However, the impact of biosimilars on the IVIG market is still evolving and may take several years to fully manifest[3].
Regional Analysis
The IVIG market, including Gammagard Liquid, is not uniform across all regions. Here are some key points:
Global Market
The global market is driven by the increasing demand in both developed and developing countries. Companies like Takeda, Grifols, and CSL have a significant presence globally[4].
Regional Variations
Prices and market dynamics can vary significantly across different regions due to differences in healthcare systems, regulatory environments, and market competition.
Key Players and Competitive Landscape
The IVIG market is dominated by several key players:
Takeda Pharmaceutical Company Limited
Takeda, with its product Gammagard Liquid, has a strong presence in the market. The recent FDA approval for treating CIDP has further strengthened its position[1].
Grifols, CSL, and Other Manufacturers
Other major players like Grifols and CSL also play a significant role in the market. These companies are continuously investing in research and development to improve their products and expand their market share[4].
Conclusion
Gammagard Liquid is a vital component of the IVIG market, which is poised for significant growth driven by increasing demand, technological advancements, and regulatory approvals. While current prices are substantial, future price projections suggest a potential for stabilization or reduction as the market evolves.
Key Takeaways
- Market Growth: The IVIG market is expected to reach USD 23.5 billion by 2034, with a CAGR of 5.76% during 2024-2034.
- Pricing: Current prices range from $188 for 10 milliliters to $3,579.59 for 200 milliliters.
- Drivers: Increase in autoimmune diseases, advancements in production technologies, and heightened awareness about IVIG therapies.
- Future Projections: Potential stabilization or reduction in prices due to technological advancements and the introduction of biosimilars.
- Key Players: Takeda, Grifols, CSL, and other manufacturers dominate the market.
FAQs
Q: What is Gammagard Liquid used for?
A: Gammagard Liquid is used to treat conditions such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy, and Primary Immunodeficiency Syndrome.
Q: How much does Gammagard Liquid cost?
A: The cost of Gammagard Liquid varies by quantity, ranging from around $188 for 10 milliliters to $3,579.59 for 200 milliliters.
Q: What are the key drivers of the IVIG market growth?
A: The key drivers include the increase in autoimmune and inflammatory diseases, advancements in production technologies, and heightened awareness about IVIG therapies.
Q: Which companies are major players in the IVIG market?
A: Major players include Takeda, Grifols, CSL, Octapharma, and others.
Q: What is the projected market size of the IVIG market by 2030?
A: The global IVIG market is forecasted to reach USD 21,530 million by 2030, with a CAGR of 7.1% during the forecast period of 2024-2030[4].
Sources
- Intravenous Immunoglobulin Market Size to Reach USD 23.5 Billion by 2034: Biospace, August 2024.
- Gammagard Liquid Prices, Coupons, Copay Cards & Patient Assistance: Drugs.com.
- Five-year analysis of the Drug Pricing Lab's Production Plus Profit Pricing: Milliman, March 2021.
- IVIg Liquid - Market, Report Size, Worth, Revenue, Growth, Industry: Valuates Reports.
More… ↓
